How MedicinesComplete supports the pharmaceutical industry
After risks to patient safety, there are financial and reputational risks associated with not having access to independent, evidence-based pharmaceutical knowledge.
In this article we share the reasons why MedicinesComplete is an essential resource for the pharmaceutical industry, taking a look at various relevant statistics.
Please complete the form at the bottom of this article to request a complimentary trial of MedicinesComplete.
Operating without a trusted source of medicines information could pose a significant risk to a business.
The financial burden of error
After endangering patient safety medication errors, a topic we have covered in other articles, can be a financial liability.
In England alone, an estimated 237 million medication errors occur annually.¹ The economic burden of “definitely avoidable” adverse drug reactions (ADRs) is estimated to cost the NHS £98.5 million per year, consuming over 180,000 bed days.²
For a pharmaceutical company such errors may lead to litigation claims.
Errors may arise during the medicine manufacturing process, for example, when the packaging is incorrectly labelled, or adulterants are introduced.
They might also be traced back to inadequate administration guidance or a failure to disclose side effects or a complex interaction.
In some specialised settings, cumulative litigation costs associated with errors have been recorded as high as £6.9 million over a period of around 20 years.²
Regulatory non-compliance and fines
The global cost of regulatory non-compliance is rising.
In 2024, the average cost of non-compliance for a multinational firm was estimated at $14.8 million (£11.8m), nearly three times the cost of maintaining high-quality compliance standards.³
In the pharmaceutical industry these failures can lead to severe financial, legal, and reputational damage. In 2023, the FDA issued 1,150 warning letters for pharmaceutical non-compliance.⁴
Without access to The MHRA Orange Guide through MedicinesComplete (providing rules and guidance for pharmaceutical manufacturers and distributors), companies could risk compliance drift.
This is where internal processes diverge from the legal requirements for manufacture and distribution. A single Good Manufacturing Practice (GMP) violation can result in an average fine of $5.3 million (£4.2m) per citation.⁵
Due diligence
In any legal challenge, a company’s primary defence is its due diligence. Relying on unverified or fragmented data sources significantly weakens this position.
Having an audit trail of decisions informed by trusted resources such as Martindale: The Complete Drug Reference or Stockley’s Drug Interactions helps to provide the evidence needed to defend clinical decisions and labelling.
From research and development to post-marketing surveillance
MedicinesComplete provides online access to trusted resources that are designed to support the drug lifecycle from research and development to post-marketing surveillance.
- Research and development and formulation: Access to Pharmaceutical Excipients allows scientists to consider and validate the properties and safety of excipients during development. This can help to prevent late-stage stability failures that can result in hundreds of millions in sunk research and development costs.
- Medical information: MI teams must provide unbiased and independent information. Martindale: The Complete Drug Reference offers global context on drugs and medicines, while Drug Administration via Enteral Feeding Tubes provides the practical guidance required for complex patient needs.
- Pharmacovigilance: Stockley’s Drug Interactions is a comprehensive resource for managing drug combinations safely. Alongside Martindale’s ADR Checker, these tools allow safety leads to identify risks before they manifest as adverse events.
- Prescribing and dispensing: British National Formulary (BNF) provides up-to-date guidance on the safe and effective use of medicines, helping to ensure evidence-based patient care and minimise the 66 million potentially clinically significant errors estimated to occur annually in England.¹
The cost of product recall
In an industry where the average cost of a product recall can range from $10 million to $100 million, the subscription cost of MedicinesComplete is a tiny fraction of the potential loss.
Subscribing to MedicinesComplete is an important step in ensuring your organisation has quick access to essential knowledge, allowing it to meet the highest standards of clinical integrity.
Trial form
Please complete the form below to request a complimentary trial to knowledge products through MedicinesComplete.
References
- Elliott RA, Camacho E, Jankovic D, Sculpher MJ, Faria R. Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Qual Saf. 2021;30(2):96-105.
2. University of Sheffield. Prevalence and economic burden of medication errors in the NHS in England. Sheffield: School of Health and Related Research (ScHARR); 2024.
3. StarCompliance. The global cost of non-compliance: 2024 data and trends. [Internet]. 2024 [cited 2026 Feb 13]. Available from: https://www.starcompliance.com/resources
4. Compliance Quest. Regulatory Compliance for Pharmaceutical Industry: A Comprehensive Guide for 2026 [cited 2026 April 22]. Available from: Regulatory Compliance for Pharmaceutical Industry | 2026 Guide
5. Pharmaceutical Business Hub. Global pharma fines and the true cost of manufacturing non-compliance. [Internet]. 2024 [cited 2026 Feb 13]. Available from: https://www.pharmabusinesshub.com/regulatory-costs
